EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

A woman who has never smoked says she was shocked to be told she had terminal lung cancer despite being “fit and healthy”.

In the latest episode of Oncology Unscripted, Dr. John Marshall addresses critical issues concerning the dosing practices in oncology, particularly questioning the prevailing approach of using maximum ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Cambridge: AstraZeneca's Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and ...